Anti-SLAMF7/CD319(Azintuxizumab Biosimilar) Antibody

Summary

Cat.No.	400-616-001
Isotype	Human IgG1
Conjugate	Unconjugated
Specificity	Human SLAMF7/CD319
Clonality	Monoclonal
Purity	Recombinant Expression and Affinity purified
Concentration	1mg/ml
Formation	Liquid, 10mM PBS (pH 7.5)
Storage	Store at –20 °C, (Avoid freeze/thaw cycles)

Description

Anti-SLAMF7/CD319(Azintuxizumab Biosimilar) Antibody is a biosimilar antibody directed against Human SLAMF7/CD319.

Benefits

High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production

Application notes

ELISA	1:5000-1:20000
Flow Cyt	1:200-1:1000

Other tested applications.

Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.

This product is for research use only and is not approved for use in humans or in clinical